Nyxoah Signs Memorandum of Understanding with Sheikh Shakhbout Medical City
Nyxoah has announced the signing of a memorandum of understanding with Sheikh Shakhbout Medical City (SSMC), a hospital in the United Arab Emirates specializing in complex and serious care. This agreement aims to strengthen Nyxoah's presence in the Middle East and to expand access to its Genio® therapy.
Strategic Collaboration
The memorandum of understanding was signed between Nyxoah SA and Sheikh Shakhbout Medical City, a subsidiary of PureHealth, the largest healthcare group in the Middle East. The agreement reflects Nyxoah's strategic orientation to collaborate with regional medical centers of excellence to expand access to its Genio® hypoglossal nerve stimulation (HGNS) therapy, while supporting the highest standards in clinical care, education, and scientific collaboration.
Establishing a Regional Hub
Nyxoah and SSMC are committed to positioning SSMC as a leading regional center for Genio therapy, supporting the development of a high-volume implantation program focused on patient-centered care. The collaboration also plans to establish SSMC as a regional training center for Genio therapy in the Middle East, aimed at supporting the training of surgeons, sleep specialists, and healthcare professionals in the region. Both parties are also exploring discussions related to clinical research and collaboration in the field of sleep apnea and the management of chronic and metabolic diseases.
Regulatory Milestones
The Genio® system received CE marking in 2019. FDA approval was obtained in August 2025 for a subgroup of adult patients suffering from moderate to severe obstructive sleep apnea with an apnea-hypopnea index greater than or equal to 15 and less than or equal to 65. The system also received CE marking for the extension of its therapeutic indications to patients with complete concentric collapse.
